Cost-effectiveness of 70-gene MammaPrint Signature in Node-Negative Breast Cancer

December 21, 2010

PUBLICATION: Am J Manag Care. 2010 Dec 1;16(12):e333-42. AUTHORS: Chen E., Tong K.B., Malin J.L. SUMMARY: 70-gene signature reclassified 29% of patients and spared 10% of patients from chemotherapy. Results of this modeling analysis suggest that treatment guided by 70-gene signature may be associated with a decrease in chemotherapy use and an increase in life expectancy when applied…

Read more

Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature

December 7, 2010

PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van’t Veer SUMMARY: Pooled analysis: In the group of 89 chemotherapy-naive patients, after a median follow-up of 7.4 years, 35 (39%) distant recurrences and 29 (33%) breast…

Read more

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer

December 1, 2010

PUBLICATION: Int J Mol Med. 2010 Dec;26(6):837-43. AUTHORS: Gevensleben H., Göhring U.J., Büttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergönenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T. SUMMARY: Thirty-two percent of patients (19/59) with a poor prognosis-signature identified…

Read more

Biological Functions of the Genes in the MammaPrint® Breast Cancer Profile Reflect the Hallmarks of Cancer

November 24, 2010

PUBLICATION: Biomarker Insights. 2010 Nov 28;5:129-38. doi: 10.4137/BMI.S6184. AUTHORS: Tian S., Roepman P., Van’t Veer L.J., Bernards R., de Snoo F., Glas A.M. SUMMARY: The study included 3090 clinical low-risk patients with unifocal and 238 patients with multifoGenes in the MammaPrint gene signature comprehensively measure the six hallmarks of cancer-related biology. This finding establishes a link between a…

Read more

MammaPrint® Translating Research into a Diagnostic Test

September 7, 2010

PUBLICATION: Molecular Diagnostics: The Key in Personalized Cancer Medicine 2010; pg. 26; Chapter 7 AUTHORS: Annuska M. Glas, Leonie Delahaye, Oscar Krijgsman SUMMARY: Book Chapter: This chapter describes all important critical steps being met for the implementation of a multi-marker microarray (MammaPrint®) as a routine diagnostic tool. Read more: MammaPrint Translating Research into a Diagnostic Test… Glas_Molecular Diagnostics:…

Read more

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

May 2, 2010

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen showed the highest survival rates compared to the…

Read more

Metastatic Potential of T1 Breast Cancer Can Be Predicted by the 70-gene MammaPrint Signature

May 1, 2010

PUBLICATION: Ann Surg Oncol. 2010 May;17(5):1406-13. doi: 10.1245/s10434-009-0902-x. Epub 2010 Jan 22. AUTHORS: Mook S., Knauer M., Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., Van’t Veer L.J., Rutgers E.J. SUMMARY: The 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities were 87% (SE 2%) and 91% (SE 2%), respectively, for the good prognosis-signature group (n…

Read more

The Predictive Value of the 70-Gene Signature for Adjuvant Chemotherapy in Early Breast Cancer

March 5, 2010

PUBLICATION: Breast Cancer Res Treat. 2010 Apr;120(3):655-61. doi: 10.1007/s10549-010-0814-2. AUTHORS: Knauer M., Mook S., Rutgers E.J., Bender R.A., Hauptmann M., van de Vijver M.J., Koornstra R.H., Bueno-de-Mesquita J.M., Linn S.C., van ‘t Veer L.J. ABSTRACT: Multigene assays have been developed and validated to determine the prognosis of breast cancer. In this study, we assessed the additional predictive value…

Read more

The 70-gene Signature as a Response Predictor for Neoadjuvant Chemotherapy in Breast Cancer

February 1, 2010

PUBLICATION: Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13. AUTHORS: Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., Vrancken Peeters M.J., van Tinteren H., Van’t Veer L.J., Rodenhuis S. SUMMARY: 144 (86%) were having a poor and 23 (14%) a good prognosis-signature. None of the good prognosis-signature patients…

Read more

Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population

January 27, 2010

PUBLICATION: Japanese Journal of Clinical Oncology, Volume 40, Issue 6, June 2010, Pages 508–512, https://doi.org/10.1093/jjco/hyp195. AUTHORS: Makoto Ishitobi, Teodora E. Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska M. Glas, Ellen van Lienen, Hideo Inaji, Laura J. Van’t Veer, Kikuya Kato SUMMARY: A small observational study in a Japanese Cohort -102 patients: 20% Low Risk / 80% High…

Read more